Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health announced that the Centers for Medicare and Medicaid Services (CMS) has increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payment year 2026. The company's HMO MA plan rating also increased to 3.5 Stars. Over 95% of Clover's Medicare Advantage membership is served through its PPO plans.
The improved rating was driven by exceptional performance in Medication Adherence, HEDIS, and CAHPS measures. Notably, Clover earned a 4.94 out of 5 Stars on HEDIS, which measures a plan's ability to deliver preventative screenings and manage various health issues.
Clover's CEO, Andrew Toy, emphasized the company's commitment to improving healthcare outcomes through technology like Clover Assistant. The higher Star rating is expected to allow Clover to reinvest in more competitive benefits, potentially driving membership growth while maintaining financial strength and care quality.
Counterpart Health, a subsidiary of Clover Health (Nasdaq: CLOV), has appointed David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will advance Counterpart's clinical strategy and product roadmap for Counterpart Assistant, an AI-powered physician enablement platform. With over two decades of experience in health technology and clinical innovation, Dr. Tsay previously held leadership roles at Cue Health, Apple, and New York-Presbyterian.
Counterpart Health's CEO, Conrad Wai, expressed confidence in Dr. Tsay's ability to accelerate the company's expansion into value-based healthcare networks. Dr. Tsay highlighted Counterpart Assistant as an innovative solution for providers looking to deliver value-based care. The platform aims to reduce the total cost of care in value-based models through advanced chronic disease management.
Clover Health (Nasdaq: CLOV) has appointed Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Brand, a New Jersey native with nearly 20 years of healthcare leadership experience, will oversee core MA operations and drive performance improvements. His focus will be on enhancing healthcare delivery in New Jersey through operational efficiencies and technological innovation.
Brand's experience includes roles at Jefferson Health Plans and Horizon Blue Cross Blue Shield of New Jersey, where he led operational transformations and implemented innovative solutions. At Clover Health, he will manage MA operations, optimize processes, and drive value-based care initiatives using advanced technology and data-driven solutions.
This appointment aligns with Clover's commitment to operational excellence and supporting local healthcare providers. The company aims to strengthen independent physicians and provide affordable, high-quality healthcare plans for seniors in New Jersey.
Counterpart Health, a subsidiary of Clover Health (NASDAQ: CLOV), has signed a multi-year agreement with The Iowa Clinic, a leading multispecialty healthcare group in the US. The Iowa Clinic, with over 250 providers across 40+ specialties, will deploy Counterpart's AI-powered physician enablement platform, Counterpart Assistant, to its Medicare Advantage and Medicare Shared Savings Program patients.
The platform will also be available to The Iowa Clinic's clinically integrated network partners in the Midwest. Counterpart will receive a per-member, per-month fee and potential incentive payments based on care management goals. The AI-enabled solution is designed to support earlier diagnosis and management of chronic diseases, with Clover Health reporting a 1,000 basis point medical cost ratio differential for members whose PCPs use Counterpart Assistant versus those who don't.
Clover Health (NASDAQ: CLOV) has appointed Thomas L. Tran to its Board of Directors and Audit Committee. Tran, with over 35 years of financial leadership in healthcare, most recently served as CFO of Upstream Care and previously as CFO of Molina Healthcare. CEO Andrew Toy highlighted Tran's expertise in strategic financial planning for public managed care organizations as a significant asset for Clover's mission of empowering physicians and improving health outcomes through technology. Tran expressed enthusiasm for Clover's innovative approach to Medicare and value-based care, stating his commitment to helping shape the company's vision.
Clover Health Investments, Corp. (Nasdaq: CLOV), a physician enablement technology company focused on Medicare, has announced its participation in the 2024 Wells Fargo Healthcare Conference. Peter Kuipers, the company's Chief Financial Officer, is scheduled to present on Wednesday, September 4, 2024, at 4:30 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through Clover Health's investor relations website. Additionally, a replay of the presentation will be made available on the same platform for those unable to attend the live event. This conference participation provides an opportunity for Clover Health to showcase its commitment to improving healthcare access for Medicare beneficiaries.
Clover Health (NASDAQ: CLOV) reported strong Q2 2024 financial results, showing significant improvements year-over-year. Total revenue grew 11% to $356.3 million, while GAAP Net Income from Continuing Operations reached $7.2 million, compared to a $28.9 million loss in Q2 2023. Adjusted EBITDA increased to $36.2 million from $9.9 million in the previous year.
The company's Insurance revenue grew 11.3% to $349.9 million, driven by strong member retention and intra-year growth. The Insurance MCR improved to 71.3% from 77.2% in Q2 2023. Based on these strong results, Clover Health has increased its full-year 2024 guidance, projecting Insurance Revenue of $1.35-$1.375 billion and Adjusted EBITDA of $50-$65 million.
Clover Health Investments, Corp. (Nasdaq: CLOV), a physician enablement technology company focused on Medicare, has announced its participation in two upcoming investor conferences. CFO Peter Kuipers will present at the 2024 KeyBanc Technology Leadership Forum on August 6, 2024, at 3:00 p.m. ET. Additionally, CEO Andrew Toy and CFO Peter Kuipers will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024, at 2:00 p.m. ET.
Both presentations will be accessible via live webcast and replay on Clover Health's investor relations website. These conferences provide an opportunity for Clover Health to showcase its innovative approach to healthcare technology and engage with investors.
Clover Health Investments, Corp. (Nasdaq: CLOV) has announced it will release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the results and business performance.
Interested parties can access the call by dialing 800-245-3047 (U.S. callers) or 203-518-9765 (international callers) using the conference ID: CLOVQ224. A live and archived webcast will be available on Clover Health's Investor Relations website for 12 months following the call.
On June 26, 2024, Clover Health announced that it has regained compliance with the Nasdaq minimum bid price requirement. The company had previously received a notice on April 2, 2024, from Nasdaq, indicating that its stock price had fallen below the required $1.00 per share. To comply, Clover Health's Class A Common Stock needed to maintain a closing bid price of at least $1.00 for 10 consecutive trading days, which it successfully achieved by June 25, 2024. Nasdaq has officially informed Clover Health that the matter is now resolved.